dataq1 wrote: ↑Fri Feb 18, 2022 3:52 pm
Perhaps I've misinterpreted the intended users of this device. My impression was that the device was NOT intended to be used by patients to self-diagnose, but rather to be used by sleep professionals as a screening device to prioritize access to a formal polysomnographic study.
Even as a screening tool, it leaves a lot to be desired.
So it's marketed as a "Quantified Self" and "IoT Home Automation" toy.
The company does not market it as a diagnostic tool <wink, wink, nudge, nudge> for good reason.
But the conclusion drawn in the paper clearly shows their intent.
(I don't know about your region of the world, but in my area the wait time for a sleep clinic study is 6-9 months. Even home studies have a 30-60 day wait.)
Pre-COVID, two years wait (per media reports).
I got lucky after I subjected myself to an ApneaLink HST (used as a CPAP selling tool).
Someone cancelled and a space opened up within 2 months.
I'm still in favor of longer observation periods (suggested by Flinders U), but running a weeks-long polysomnographic study is just not practical. !
Whether the Withings device is reliable is still (to my mind) questionable, but should be studied.
There are already PAT based tests in the market that can do multi-night testing.
Testing which can diagnose mild apnea unlike this toy.
https://en.wikipedia.org/wiki/Peripheral_Arterial_Tone
It's a shame they aren't being used as such but ... profits (OTOH no profit, no tools)
The major strike against NightOwl HST is that it was validated against "MICHELE SLEEP SCORING SYSTEM" (
https://www.cerebra.health/)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175785/
So it's 87% (correlation against MSSS) multiplied against whatever correlation MSSS had against the gold standard PSG.